Mirtabene (Mirtazapine)

Mirtazapine, the active ingredient in Mirtabene, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It treats major depressive disorder in adults. GNH USA supplies Mirtabene as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is indicated for major depressive disorder, a condition affecting mood and functional capacity. - Major depressive disorder: alleviates depressive symptoms and improves overall mood and daily functioning.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Serotonin syndrome, especially with other serotonergic agents - Suicidal thoughts or behavior - Severe hypotension - Hepatic dysfunction

Mirtazapine requires careful monitoring in several clinical situations. - Monitor mood: watch for worsening depression or emergence of suicidal thoughts. - Assess liver function: use cautiously in patients with hepatic impairment. - Elderly patients: increased risk of sedation and falls; start at low dose. - Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal. - Pregnancy and breastfeeding: evaluate risk‑benefit before use. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Mirtazapine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension or serotonin syndrome. - Linezolid or other reversible MAO‑A inhibitors. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): heightened serotonin syndrome risk.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, alcohol): may increase sedation. - Antihypertensive drugs: additive blood‑pressure lowering effect. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise mirtazapine plasma levels. - Alcohol: can potentiate central nervous system depression.